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The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid
(FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically
resected stage II or III colon or rectal cancer were eligible. The study had a 2 2 factorial design with four treatment arms: (a) 5FU
alone, (b) 5FUþLEV, (c) 5FUþFA, (d) 5FUþLEVþFA, and two planned comparisons, testing the role of LEV and of FA,
respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a
significant disease-free (DFS) or overall (OAS) survival advantage. The hazard ratio (HR) of relapse was 0.89 (95% confidence
intervals (CI): 0.73–1.09) for patients receiving FA and 0.99 (95% CI 0.80–1.21) for those receiving LEV; corresponding HRs of death
were 1.02 (95% CI: 0.80–1.30) and 0.94 (95% CI 0.73–1.20). Nonhaematological toxicity (all grade vomiting, diarrhoea, mucositis,
congiuntivitis, skin, fever and fatigue) was significantly worse with FA, while all other toxicities were similar. In the present trial, there
was no evidence that the addition of FA or LEV significantly prolongs DFS and OAS of radically resected colorectal cancer patients.
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Colorectal cancer is the third most frequent cause of death for
neoplasm in Western countries. After radical resection, about 30%
of stage II and 50% of stage III patients are expected to develop
recurrent disease, mostly during the first 5 years after surgery.
Adjuvant treatment has been demonstrated to prolong disease-free
(DFS) and overall survival (OAS).
When the present trial was planned, the efficacy of adjuvant
chemotherapy in prolonging DFS and OAS of colon and rectal
cancer patients had been just demonstrated, but the best regimen
was far to be identified.
Mostly based on the results of the Intergroup-0035 trial (Laurie
et al, 1989; Moertel et al 1990), that found a survival advantage for
the combination 5-fluorouracil (5FU)þlevamisol (LEV) as com-
pared to an observation arm, the National Cancer Institute (NCI)
Consensus Conference, in 1990, adopted 5FUþLEV as the
standard therapy for patients with resected stage III colon cancer
(NIH Consensus Conference, 1990). The NCI Consensus Con-
ference confirmed postoperative pelvic irradiation plus 5FU-based
regimens to be the standard treatment for stages II and III rectal
cancer, as indicated by the results of many published studies
(GITSG, 1985; Krook et al, 1991).
Most of the trials started after the Consensus Conference,
adopted the regimen 5FUþLEV as the standard arm; however,
such strategy was never substantiated by the evidence of additive
effects of the two drugs, or by the activity of the combination in the
metastatic setting. Consequently, it was felt that more evidence was
needed to evaluate the effect of this combination.
On the other hand, it was known that biomodulation of 5FU
with folinic acid (FA), significantly increased response rate in
advanced colorectal cancer (Advanced Colorectal Cancer Meta-
Analysis Project, 1992), when compared with single agents 5FU,
even though no clear evidence was available on survival.
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the independent role of LEV and FA, when combined with 5FU,
in the adjuvant treatment of colorectal cancer patients. In order to
reduce the possible confounding variables, we adopted the
schedule of 5FU suggested by the INT-0035 trial and we decided
to maintain it either in the arm of 5FU alone or in the arms of 5FU
plus LEV and/or FA.
MATERIALS AND METHODS
Study design and statistical methods
The randomised multicentre Inter-Group Centro-Sud in COLo-
rectal cancer (IGCS-COL) study was a 2 2 factorial trial
addressing two questions: (1) efficacy of addition of LEV and (2)
efficacy of addition of FA, to 5FU chemotherapy. Subjects were
randomly assigned to one of four treatment arms (5FU alone,
5FUþLEV, 5FUþFA, 5FUþLEVþFA). IGCS-COL derived, in
September 1993, from the combination of two previous indepen-
dent multicentre trials, both started in 1991, and both funded by
the Italian National Research Council (CNR). The first study was
coordinated by the Gruppo Oncologico Centro Sud Isole – Gruppo
Cooperativo Oncologico Siciliano (GOCSI-GruCOS), and the
second one by the NCI in Rome – Institute Regina Elena (IRE).
Decision of merging the two trials was prompted by the scientific
committee of the funding agency because of the lower than
expected enrolment rate and the factorial design of the two studies,
that shared the question on FA. Main characteristics of the three
studies are reported in Table 1.
From the start, the GOCSI-GruCOS trial addressed both the
questions on LEV and FA, but chemotherapy administration was
planned for 1 year. Centralised randomisation was stratified by
tumour stage (II, III) and site (colon, rectum).
Conversely, together with the evaluation of FA, the IRE trial
addressed the question of the efficacy of the addition of
chemotherapy (with mitomycin Cþ5FU) given through portal
vein infusion to systemic treatment given for 6 months; patients
with rectal cancer were not eligible. Centralised randomisation was
stratified by centre.
In September 1993, the two trials were joined under the
nickname IGCS-COL (Inter-Gruppo Centro Sud – COLorectal)
with a common amended protocol with the following characteris-
tics: (a) the study had a factorial design with two questions that
addressed the role of LEV and the role of FA, with four treatment
arms (5FU alone, 5FUþLEV, 5FUþFA, 5FUþLEVþFA); (b) the
duration of chemotherapy was established to 6 months in all arms;
(c) patients with stage II or III colon or rectal cancer were eligible;
(d) stage and tumour site were used as strata for randomisation.
The portal vein infusion arms of the IRE trial were closed and are
not accounted for in this analysis.
Randomisation was centralised at the two data centres, in Naples
for GOCSI-GRUCOS centres and in Rome for IRE centres.
Treatment allocation used random permuted blocks of variable
size within four strata built with tumour stage (II or III) and site
(colon or rectum).
With 5% type I error and 80% power of detecting a hazard ratio
(HR) of relapse of 0.75 (from 50 to 60% DFS at 5 years), an
expected enrolment duration of 7 years and a mean rate of 15
patients per month, 1250 patients had to be recruited and 383
events had to be observed. For the same HR to be detected in
overall survival (from 60 to 68% OAS at 5 years), 314 events were
needed.
Analyses were conducted on an intention-to-treat basis. DFS was
defined as the interval elapsed between date of randomisation
and date of the first tumour relapse (local or distant recurrence) or
the date of death without relapse. Patients who were diagnosed a
second primary during follow-up were censored at the date of such
diagnosis. Overall survival was defined as the interval between date
of randomisation and the date of death for any cause or the date of
the last information on vital status.
Although results were reported for the four treatment arms,
only two comparisons were planned, for FA and LEV efficacy,
respectively. Survival curves were drawn by the Kaplan–Meier
method and statistical significance of the differences was
calculated by log-rank test. Cox multivariable regression model
Table 1 Synopsis of the main characteristics of the trials before and after merging
IRE trial GOCSI-GruCOS trial IGCS-COL trial
Main questions (1) Efficacy of adjuvant PVI (1) Efficacy of 5FU modulation with LEV (1) Efficacy of 5FU modulation with LEV
(2) Efficacy of 5FU modulation with FA (2) Efficacy of 5FU modulation with FA (2) Efficacy of 5FU modulation with FA
Patients included Colon cancer, TNM stage II or III; age
18–75 years; PS 0–2
Colon or rectal cancer, TNM stage II or
III; age 18–75 years; PS 0–2
Colon or rectal cancer, TNM stage II or
III; age 18–75 years; PS 0–2
Study design Phase 3, 2 2 factorial design Phase 3, 2 2 factorial design Phase 3, 2 2 factorial design
Portal vein chemotherapy Mitomycin C+5FU None None
Systemic chemotherapy 5FU+LEV 5FU 5FU
5FU+LEV+PVI 5FU+LEV 5FU+LEV
5FU+LEV+FA 5FU+FA 5FU+FA
5FU+LEV+FA+PVI 5FU+LEV+FA 5FU+LEV+FA
Randomisation Centralised, during surgery, stratified by
centre
Centralised, after surgery, stratified by
tumour site and stage
Centralised, after surgery, stratified by
tumour site and stage
Duration of systemic chemotherapy 6 months 12 months 6 months
Timing of follow-up Every 3 months for years 1–2, every 6
months for years 3–10, annually
thereafter
Every 3 months for years 1–2, every 6
months for years 3–10, annually
thereafter
Every 3 months for years 1–2, every 6
months for years 3–10, annually
thereafter
Time of accrual March 1991–August 1993 March 1991–August 1993 September 1993–1998
5FU¼5-fluorouracil; LEV¼levamisol; PVI¼portal vein infusion; PS¼performance status.
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swas adjusted by major prognostic factors (sex, stage, site of
primary, grade of differentiation) stratified by site of coordination
(Naples or Rome) and period of study (before or after fusion). HRs
of relapse and death were estimated with 95% confidence intervals
(CI). All P-values are two sided. Toxicity grades were compared by
means of exact Wilcoxon–Mann–Whitney test.
Analyses were performed with the S-PLUS 2000 Professional
statistical software package (MathSoft Inc., Seattle, WA, USA) and
the StatXact-5 software (Cytel Software Corporation).
Patients
To be eligible the patients had to meet the following criteria:
histological proof of radically resected (no evidence of gross or
microscopic residual disease) colon or rectal cancer; TNM stage II
or III; age 18–75 years; ECOG Performance Status not worse than
2; no previous malignancy or chemotherapy; blood, liver, renal and
cardiac function within normal ranges. All patients had to give oral
consent to randomisation.
Treatments
The schedule of 5FU administration was mutuated from the
Intergroup trial (Laurie et al, 1989) for all the four treatment arms:
(a) 5FU 450mgm
 2 i.v. bolus from days 1 to 5, then, from day 28,
once weekly, for 6 months; (b) 5FU 450mgm
 2 i.v. bolus from
days 1 to 5, then, from day 28, once weekly, for 6 monthsþLEV
150mgdie
 1 orally for 3 consecutive days every 2 weeks for 6
months; (c) 5FU 450mgm
 2 i.v. bolus from days 1 to 5, then, from
day 28, once weekly, for 6 monthsþFA (L-isomer) 100mgm
 2 i.v.
90–120min infusion before 5FU administration; (d) 5FU
450mgm
 2 i.v. bolus from days 1 to 5, then, from day 28, once
weeklyþLEV 150mgdie
 1 orally for 3 consecutive days every 2
weeksþFA (L-isomer) 100mgm
 2 i.v. 90–120min infusion before
5FU administration, for 6 months. The dose of FA was doubled
(200mgm
 2) if the racemic (DL) isomer was used.
For rectal cancer patients, external pelvic radiation therapy
(1.8Gyday
 1 for 5daysweek
 1 for 5 weeks, i.e. a total dose of
45Gy) was planned after surgery.
Toxicity assessment
Toxicity was assessed at each chemotherapy administration, and
codified according to WHO criteria (Miller et al, 1981). The dose of
5FU was modified depending on the type and the severity of
adverse events. General rules of dose modification were: (a) in case
of haematological toxicity, chemotherapy was held for a week,
and resumed with the full dose if toxicity was grade 0, or with a
reduced dose in case of persistent toxicity (75% of the initial dose
with grade 1 or 50% of the initial dose with grade 2); (b) in case of
nonhaematological toxicity, chemotherapy was held until complete
resolution of the adverse event, for a maximum of 3 weeks; after 3
weeks, if toxicity was still present, the treatment was discontinued.
Follow-up
All patients were followed every 3 months during the first 2 years,
every 6 months from years 3 to 10, and annually thereafter. The
follow-up evaluation included: physical examination, complete
haematology and chemistry every 6 months, colonoscopy, liver
ultrasound, and chest X-rays yearly.
RESULTS
Patients characteristics
From March 1991, to September 1998, 1327 patients were assigned
5FU alone (308 patients, 23.2%), 5FUþLEV (357 patients, 26.9%),
5FUþFA (312 patients, 23.5%) or 5FUþLEVþFA (350 patients,
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Allocated to FU: 308°
Ineligible (included)
Wrong stage: 1
Older than 75 years: 1
Lost at randomisation: 26
Dead: 67
Alive: 215
Followed < 6 months: 19
Followed  6–24  months: 23
Followed > 24 months: 173
Randomised: 1327
Allocated to FULEV: 357
Ineligible (included)
Older than 75 years: 3
Lost at randomisation: 35
Dead: 65
Alive: 257
Followed < 6 months: 5
Followed  6–24  months: 43
Followed > 24 months: 209
Allocated to FUFA: 312°
Ineligible (included)
Older than 75 years: 1
Lost at randomisation: 28
Dead: 67
Alive: 217
Followed < 6 months: 9
Followed  6–24  months: 31
Followed > 24 months: 177
Followed < 6 months: 11
Followed  6–24  months: 39
Followed > 24 months: 196
Allocated to FUFALEV: 350
Ineligible (included)
Wrong stage: 2
Older than 75 years: 1
Lost at randomisation: 39
Dead: 65
Alive: 246
Analysed for FA efficacy: 350
Analysed for FA toxicity: 296*
Analysed for LEV efficacy: 300** 
Analysed for LEV toxicity: 252*
Analysed for FA efficacy: 308
Analysed for FA toxicity: 269*
Analysed for LEV efficacy: 308
Analysed for LEV toxicity: 269*
Analysed for FA efficacy: 357
Analysed for FA toxicity: 310*
Analysed for LEV efficacy: 311** 
Analysed for LEV toxicity: 270*
Analysed for FA efficacy: 312
Analysed for FA toxicity: 268*
Analysed for LEV efficacy: 312
Analysed for LEV toxicity: 268*
° These arms were not available in the IRE trial before 1st, September 1993.
* Due to missing data,  ** Due to the exclusion of patients randomised in the IRE trial before 1st, September 1993.
Figure 1 Study flow according to CONSORT.
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Variable 5FU 5FU-LEV 5FU-FA 5FU-FA-LEV Total
n¼308 n¼357 n¼312 n¼350 n¼1327
Median age (range), years 61 (22–76) 61 (26–78) 61 (26–76) 60 (25–76) 61 (22–78)
Gender, n (%)
Male 157 (51) 173 (48) 164 (53) 210 (60) 704 (53)
Female 151 (49) 184 (52) 148 (47) 140 (40) 623 (47)
Site, n (%)
Colon 242 (79) 292 (82) 245 (79) 292 (83) 1071 (81)
Rectum 66 (21) 65 (18) 67 (21) 58 (17) 256 (19)
AJCC/UICC stage, n (%)
II 144 (47) 166 (46) 145 (46) 169 (48) 624 (47)
III 164 (53) 190 (53) 167 (54) 180 (51) 701 (53)
Unknown — 1 (o1) — 1 (o1) 2 (o1)
Tumour type, n (%)
Adenocarcinoma 252 (82) 286 (80) 256 (82) 278 (79) 1072 (81)
Mucinous 23 (7) 30 (8) 19 (6) 27 (8) 99 (7)
Other 5 (2) 2 (1) 3 (1) 4 (1) 14 (1)
Unknown 28 (9) 39 (11) 34 (11) 41 (12) 142 (11)
Tumour grade, n (%)
Well differentiated 18 (6) 21 (6) 6 (2) 17 (5) 62 (5)
Intermediate 213 (69) 227 (64) 216 (69) 237 (68) 893 (67)
Poorly differentiated 41 (13) 52 (15) 44 (14) 49 (14) 186 (14)
Unknown 36 (12) 57 (16) 46 (15) 47 (13) 186 (14)
Site and period of trial coordination, n (%)
Naples, before fusion 56 (18) 56 (16) 54 (17) 56 (16) 222 (17)
Rome, before fusion — 46 (13) — 50 (14) 96 (7)
Naples, after fusion 202 (66) 195 (55) 200 (64) 197 (56) 794 (60)
Rome, after fusion 50 (16) 60 (17) 58 (19) 47 (13) 215 (16)
Table 3 Description of events by treatment arm
Type of event 5FU 5FU-LEV 5FU-FA 5FU-FA-LEV Total
n¼308 n¼357 n¼312 n¼350 n¼1327
First event, n (%)
Locoregional relapse
Anastomosis or perianastomosis 5 (1.6) 2 (0.6) 2 (0.6) 5 (1.4) 14 (1.1)
Abdominal or pelvic lymphnodes 4 (1.2) 3 (0.8) 2 (0.6) 6 (1.7) 15 (1.1)
Abdominal or pelvic masses 17 (5.5) 22 (6.1) 15 (4.8) 17 (4.9) 71 (5.3)
Peritoneal carcinosis 7 (2.3) 4 (1.1) 2 (0.6) 4 (1.1) 17 (1.3)
Distant metastases
Liver 28 (9.1) 32 (9.0) 27 (8.6) 31 (8.9) 118 (8.9)
Lung 7 (2.3) 8 (2.2) 9 (2.9) 4 (1.1) 28 (2.1)
Bone 2 (0.6) 2 (0.6) 1 (0.3) 2 (0.6) 7 (0.5)
Soft tissues 1 (0.3) 1 (0.3) — 1 (0.3) 3 (0.2)
Combination of distant sites 8 (2.6) 2 (0.6) 5 (1.6) 5 (1.4) 20 (1.5)
Locoregional+distant 11 (3.6) 10 (2.8) 7 (2.2) 10 (2.9) 38 (2.9)
Other or unknown site 3 (1.0) 8 (2.2) 6 (1.9) 6 (1.7) 23 (1.7)
Death without relapse 10 (3.2) 13 (3.6) 12 (3.8) 8 (2.3) 43 (3.2)
Death, n (%) 67 (21.7) 65 (18.2) 67 (21.5) 65 (18.6) 264 (19.9)
Second primary, n (%)
Colorectal 3 (1.0) 2 (0.6) 2 (0.6) 5 (1.4) 12 (0.9)
Leukemia — 1 (0.3) — — 1 (0.07)
Breast 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3) 4 (0.3)
Lung — 1 (0.3) 1 (0.3) 1 (0.3) 3 (0.2)
Thymoma 1 (0.3) — — — 1 (0.07)
Bladder — 1 (0.3) — — 1 (0.07)
Prostate — — 1 (0.3) 1 (0.3) 2 (0.1)
Thyroid — — 2 (0.6) — 2 (0.1)
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s26.4%). Nine patients were found ineligible after randomisation
because of age (6 patients) or wrong stage (3 patients), but were
included in the analysis (Figure 1). Overall 80% of patients had
colon cancer and 20% rectal cancer; patients’ characteristics by
treatment arm are shown in Table 2.
Efficacy
By the end of 2003, 397 patients relapsed and 264 patients died.
Details of outcome events by treatment arm are reported in
Table 3. The number and the site of first loco-regional relapse or
distant metastases and the number of deaths were similar among
the four treatment arms. Overall, 26 (2.0%) second primary
tumours (12 colorectal, four breast, three lung, two prostate, two
thyroid, one thymoma, one bladder, one leukaemia) were
diagnosed during follow-up, with a similar distribution among
the arms.
Neither the addition of LEV, nor the addition of FA, to 5FU,
significantly affected DFS and OAS, at univariable and multi-
variable analyses. For patients receiving LEV, the HR of relapse
was 0.99 (95% CI 0.81–1.21) and that of death was 0.94 (95% CI
0.73–1.20) at multivariable analysis. For patients receiving FA, the
HR of relapse was 0.89 (95% CI 0.73–1.09) and that of death was
1.02 (95% 0.80–1.30) at multivariable analysis. Estimated DFS was
71 and 63% for patients receiving LEV compared with 71 and
64% for those not receiving LEV, at 3 and 5 years, respectively.
Estimated DFS was 73 and 65% for patients receiving FA compared
with 71 and 64% for those not receiving FA, at 3 and 5 years,
respectively.
DFS and OAS curves, scattered by the four treatment arms, are
reported in Figure 2.
Unadjusted HRs from an exploratory subgroups analysis are
reported in Figures 3 and 4 for LEV and FA, respectively. No effect
of LEV was observed in any subgroup; an apparent heterogeneity
of FA effect on DFS was observed according to sex and stage, with
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Figure 2 Disease-free (left) and overall survival (right) curves by treatment arms (solid¼5FU, dotted¼5FUþLEV, dotted/dashed¼5FUþFA,
dashed¼5FUþLEVþFA).
Hazard ratio of recurrence
0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8
Hazard ratio of death
All patients (n = 1231)
Colon (n = 975)
Rectum (n = 256)
Site
<65 years (n =  738)
65 years or older (n = 493)
Age
Males (n = 654)
Females (n = 577)
Sex
TNM II (n = 575)
TNM III (n = 656)
Stage
LEV
Better
Control
Better
LEV
Better
Control
Better
Figure 3 Unadjusted hazard ratio of relapse (left) and death (right) for patients receiving LEV vs those not receiving it. Horizontal bars represent 95% CI;
size of the diamond is proportional to the size of the subgroup.
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the interaction tests were not statistically significant (P¼0.09 and
0.10, respectively).
Toxicity
Overall 13 toxic deaths (1%) were reported, with no significant
difference among treatments. Toxicity, scattered by the four
treatment arms, is summarised in Table 4. The addition of FA
significantly worsened vomiting, diarrhoea, fever, mucositis,
alopecia, skin and ocular toxicity. On the contrary, LEV did not
produce any statistically significant effect on pattern of toxicity.
DISCUSSION
In the present trial, we found no evidence of DFS or OAS
improvement by adding LEV or FA to 5FU in the adjuvant
treatment of patients with stage II or III colon or rectal cancer.
Conversely, the addition of FA substantially increased toxicity.
As many trials published or planned at the beginning of 1990s,
we pooled together patients with colon and rectal cancer
(Panettiere et al, 1988; Laurie et al, 1989; Quasar Collaborative
Group, 2000; Taal et al, 2001) and stage II or III disease (Laurie
et al, 1989; Moertel et al, 1990; Wolmark et al 1993, 1999; Quasar
Collaborative roup, 2000; Di Costanzo et al, 2003; Andre ` et al,
2004). Exploratory subgroup analyses suggest that no significant
heterogeneity existed in the effect of both LEV and FA across
subgroups that could represent clinically relevant populations.
This means that the primary results of the analysis hold true for
almost all of the subgroups; although a positive effect seems
evident for FA in reducing the hazard of relapse in stage II
patients, such figures must be considered with caution because
of the reduced sample size typical of subgroup analyses and of
the obvious increased risk of false-positive results with multiple
testing. However, it is important to stress that about 90% of
patients with stage II colon cancer entered in this trial met criteria
recently proposed by ASCO to select stage II patients candidate to
adjuvant chemotherapy (Benson AB III et al, 2004).
5FU is still the mainstay of adjuvant treatment of colorectal
cancer. Thus, the question of possible efficacy of its modulation is
still actual.
Our data, that LEV does not significantly modify efficacy as well
as toxicity of 5FU, are consistent with several other studies that
did not find any improvement by adding LEV to 5FU both in colon
(Wolmark et al, 1999; Quasar Collaborative Group, 2000; Cascinu
et al, 2003) and in rectal cancer patients (Tepper et al, 2002);
indeed, 5FUþLEV has been abandoned in clinical practice and is
no more considered as a standard arm in clinical trials.
On the contrary, FA is still considered as a part of treatment
schedules that include 5FU, in all ongoing trials with new drugs. In
the MOSAIC study, the combination of 5FUþFA combined with
oxaliplatin has shown higher efficacy than 5FUþFA alone, with a
5.3% reduction of the probability of recurrence at 3 years (Andre `
et al, 2004). Trials adding irinotecan to 5FUþFA are ongoing and
efficacy data are expected.
Our data are consistent with the results of many randomised
trials (O’Connell et al, 1998; Bleeker et al, 2000; Di Costanzo et al,
2003) exploring the efficacy of the addition of FA to a 5FU-based
regimen as adjuvant chemotherapy for colon cancer patients,
which failed to demonstrate any benefit from the addition of FA.
On the other hand, few studies showed the superiority of the
combination 5FUþFA in terms of DFS or OAS when compared
to 5FUþLEV (Wolmark et al, 1999; Arkenau et al, 2003). Overall,
such contrasting data are consistent with the hypothesis that the
effect of FA on efficacy, if any, is small, while the worsening effect
on gastrointestinal toxicity is a common finding, well described in
most papers (O’Connell et al, 1998; Bleeker et al, 2000; Porschen
et al, 2001; Di Costanzo et al, 2003).
Although our study was not powered to detect any difference
in the subgroup of rectal cancer patients, our finding that the
addition of FA or LEV to 5FU produces no benefit, together with
the results of the Intergroup-0114 trial (Tepper et al, 2002) and
with the early report of the Intergroup-144 study (Smalley et al,
2003) reinforce the evidence that 5FU modulation is ineffective in
rectal cancer.
On these grounds, it should be discussed whether such a small
benefit may be considered still worth with schedules including
new drugs (i.e. oxaliplatin or irinotecan) that may produce
improvement of efficacy at a larger extent than that hypothesised
for FA; in addition, with such schedules, worsening of toxicity
induced by FA may become more critical for patients manage-
ment, and ultimately prevent administration at full dose of more
active drugs.
Hazard ratio of recurrence
0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8
Hazard ratio of death
All patients (n = 1327)
Colon (n = 1071)
Rectum (n = 256)
Site
<65 years (n = 790)
65 years or older (n = 537)
Age
Males (n = 704)
Females (n = 623)
Sex
TNM II (n = 624)
TNM III (n = 701)
Stage
FA
Better
Control
Better
FA
Better
Control
Better
Figure 4 Unadjusted hazard ratio of relapse (left) and death (right) for patients receiving FA vs those not receiving it. Horizontal bars represent 95% CI;
size of the diamond is proportional to the size of the subgroup.
Adjuvant chemotherapy in colorectal cancer
S De Placido et al
901
British Journal of Cancer (2005) 93(8), 896–904 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sTable 4 Percentage of patients experiencing toxicity by treatment arm according to WHO grades
5FU 5FU-LEV 5FU-FA 5FU-FA-LEV
P-value P-value
n¼269 n¼310 n¼268 n¼296
FA effect (n¼1143) LEV effect (n¼1059)
Type of toxicity G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 all grades all grades
Vomiting 15 4 0.4 — 17 7 0.3 0.6 17 8.6 1.9 0.4 22 8.4 1 0.3 0.004 0.11
Diarrhoea 13 5.9 2.2 — 12 11 3.5 — 10 19 9 1 12 15 8 1.7 o0.0001 0.56
Mucositis 8.9 3 0.3 0.3 9.7 5.8 0.9 — 16 8.2 9.7 2.2 17 13 3.7 2.7 o0.0001 0.24
Fever — — — — — 0.3 0.3 — 1.5 0.7 0.3 — 1 1 0.3 0.3 0.0017 0.35
Leukopenia 8.6 6.3 0.7 0.3 9.4 6.8 0.9 — 9.3 5.2 1.9 0.7 8.8 5.4 0.3 1 0.92 0.77
Anemia 2.6 — — — 1.9 1.3 — — 4.5 1.1 — — 3.7 0.7 — — 0.09 0.75
Thrombocytopenia 3.3 0.3 — — 2.6 0.3 0.3 — 2.2 0.3 0.3 — 1 — 0.3 — 0.20 0.48
Skin 3.3 0.3 — — 3.5 2.3 — — 6.3 3.7 1.1 — 6.8 4.4 1 — o0.0001 0.29
Congiuntivitis — — — — 0.6 — — — 1.9 1.9 — — 3 0.7 — — o0.0001 0.77
Alopecia 1.5 0.3 — — 1.3 0.6 — — 3.4 1.1 1.1 — 2.4 3 0.3 — 0.0007 0.96
Abdominal pain 1.1 — — — 1.3 0.3 — — 0.3 0.3 0.3 — 2 — — — 0.70 0.55
Anorexia — — — — 0.3 — — — — — — — 0.3 — — — 0.99 —
Taste alteration 0.3 — — — — — — — 0.3 — — — — — — — 0.99 0.51
Gastric ulcer — — — 0.3 — 0.3 — — — — — — — — — — 0.49 0.99
GI tract bleeding 0.3 — 0.3 — — — — — 0.3 — — — — — — — 0.87 0.26
Constipation 0.3 — — — 1 0.3 0.3 — — 0.7 — — 0.7 0.7 — — 0.96 0.11
Bilirubin 1.1 0.3 — — 0.9 0.3 — — 0.7 0.3 — — 1 0.3 — — 0.96 0.99
Hypertransaminasaemia 2.2 0.3 — — 1.6 0.3 0.3 — 1.1 — — — 1.4 0.3 — — 0.22 0.75
Headhache — — — — — — — — — — — — 0.6 — — — 0.25 0.49
Fatigue 0.7 — — — 0.6 — — — 2.6 — — — 1.4 0.3 — — 0.04 0.85
Cardiac 1.1 — — 1.1 0.6 — — 0.3 0.3 0.3 — 0.7 — 0.3 — 0.3 0.57 0.23
Neurotoxicity — — — — 0.3 0.3 — 0.3 0.3 — — 1.1 0.7 — — 0.7 0.10 0.48
Cistitis — — 0.3 — 0.3 0.3 — — 0.3 — — — 0.7 — — — 0.99 0.95
Renal 0.3 — — — 0.6 — — — 0.3 — — — 0.7 — — — 0.99 0.97
Vascular — 0.3 — — — 0.3 0.3 — — 0.3 — — — — — — 0.57 0.99
Allergy — — — — 0.3 — — — — — — — 0.7 — — — 0.61 0.24
Other — — — — 0.6 — — — 0.3 0.3 — — 1.4 — — — 0.14 0.43
Toxic death 4 (1.5 %) 1 (0.3 %) 5 (1.9 %) 3 (1.0 %) 0.42 0.26
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sUnfortunately, there are no ongoing trials that add new
drugs to 5FU alone. Indirect evidence could be mutuated by
results recently appearing on clinical trials with capecitabine. This
drug mimics a continuous infusion of 5FU, and is given without
any modulating agent. The recently published results of the X-ACT
trial showed a slightly significant advantage in terms of 3 years risk
of relapse (HR¼0.87, CI 0.75–1.00) and of death (HR¼0.84, CI
0.69–1.01) for patients treated with adjuvant capecitabine with
respect to those treated with standard 5FU-FA (Twelves et al,
2005). Safety profile, for both gastrointestinal and haematological
side effects, was improved with capecitabine (Scheithauer et al,
2003). Such data, together with a randomised phase II trial of
capecitabine in metastatic colorectal cancer suggesting that the
addition of FA does not improve activity but worsen toxicity (Van
Cutsem et al, 2000), support the hypothesis that modulation with
FA might not be necessary and future trials should take into
consideration the possibility of removing it from standard
regimens.
ACKNOWLEDGEMENTS
The study was partially supported by a CNR-ACRO PF (Consiglio
Nazionale delle Ricerche, Progetto Finalizzato Applicazioni
Cliniche della Ricerca Oncologica) grant.
REFERENCES
Advanced Colorectal Cancer Meta-analysis Project (1992) Modulation of
fluorouracil by leucovorin in patients with advanced colorectal cancer:
evidence in terms of response rate. J Clin Oncol 10: 896–903
Andre ` T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T,
topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, De
Gramont A (2004) Oxaliplatin, fluorouracil and leucovorin as adjuvant
traetment for colon cancer. N Engl J Med 35: 2343–2351
Arkenau HT, Bermann A, Retting K, Strohmeyer G, Porschen R, on behalf
of the Arbeitsgemeinschaft Gastrointestinale Onkologie (2003) 5-
Fluorouracil plus Leucovorin is an effective adjuvant chemotherapy in
curatively resected stage III colon cancer: long-term follow-up results of
the adjCCa-01 trial. Ann Oncol 14: 395–399
Benson III AB, Schrag D, Somerfield MR, Cohen AM, Figuerado AT, Flynn
PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers
M, Charrette M, Haller DG (2004) American Society of Clinical Oncology
recommendations on adjuvant chemotherapy for stage II colon cancer.
J Clin Oncol 22: 1–12
Bleeker WA, Mulder NH, Hermans J, Otter R, Plukker JT, for the IKN Colon
Trial Group (2000) The addition of low-dose leucovorin to the
combination of 5-fluorouracil-levamisole does not improve survival in
the adjuvant treatment of Dukes’ C colon cancer. Ann Oncol 11: 547–552
Cascinu S, Catalano V, Piga A, Mattioli R, Marcellini M, Pancotti A,
Bastioni R, Torresi U, Silva RR, Pieroni V, Giorni F, Catalano G,
Cellerino R (2003) The role of levamisole in the adjuvant treatment of
stage III colon cancer patients: a randomised trial of 5-fluorouracil and
levamisole vs 5-fluorouracile alone. Cancer Invest 21: 701–707
Di Costanzo F, Sobrero A, Gasperoni S, Dogliotti L, Frassineti L, Falcone A,
Lionetto R, Brizzi P, Lippi G, Gallo L, Conte P, Comandone A, Turci D,
Mrzola M, Folco U, Pfanner E, Mestriner M, Boni C, Galli C, Tonato M,
Rosso R (2003) Adjuvant chemotherapy in the treatment of colon cancer:
randomised multicentre trial of the Italian National Intergroup of
Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol 14:
1365–1372
Gastrointestinal Tumor Study Group (1985) Prolongation of the disease-
free interval in surgically treated rectal cancer carcinoma. N Eng J Med
312: 1465–1472
Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW,
Kubista TP, Poon MA, Meyers WC, Mailliard JA, Twito DI, Morton RF,
Veeder MH, Witzig TE, Cha S, Vidyarti SC (1991) Effective surgical
adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:
709–715
Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh J, Rubin J,
McCormack GW, Gersten JB, Krook JE, Malliard J, Twito DI, Morton RF,
Tschetter LK, Barlow JF (1989) Surgical adjuvant therapy of large-bowel
carcinoma: an evaluation of levamisole and the combination of
levamisole and fluorouracil. The North Central Cancer Treatment Group
and the Mayo Clinic. J Clin Oncol 7: 1447–1456
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of
cancer treatment. Cancer 47: 207–214
Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman
PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH,
Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of
resected colon carcinoma. N Engl J Med 322: 352–358
NIH Consensus Conference (1990) Adjuvant therapy for patients with
colon and rectal cancer. JAMA 264: 1444–1450
O’Connell M, Laurie JA, Kahn M, Fitzgibbons RJ, Erlichman C, Shepherd L,
Moertel CG, Kocha WI, Pazdur R, Wieand S, Rubin J, Vukov AM,
Donohue JH, Krook JE, Figuerado A (1998) Prospectively randomised
trial of postoperative adjuvant chemotherapy in patients with high-risk
colon cancer. J Clin Oncol 16: 295–300
Panettiere FJ, Goodman PJ, Costanzi JJ, Cruz AB, Vaitkevicius VK,
McCracken JD, Brownlee RW, Laufman L, Stephens RL, Bonnet J,
Bottomley R, Rivkin S, Fletcher W, Oishi N, Chen TT (1988) Adjuvant
therapy in large bowel adenocarcinoma: long-term results of a Southwest
Oncology Group Study. J Clin Oncol 6: 947–954
Porschen R, Bermann A, Loffler T, Haack G, Retting K, Anger Y,
Strohmeyer G, for the the Arbeitsgemeinschaft Gastrointestinale
Onkologie (2001) Fluorouracil plus leucovorin as effective adjuvant
chemotherapy in curatively resected stage III colon cancer: results of the
trial adjCCa-01. J Clin Oncol 19: 1787–1794
Quasar Collaborative Group (2000) Comparison of fluorouracil with
additional levamisole, higher-dose folinic acid, or both as adjuvant
chemotherapy for colorectal cancer: a randomised trial. Lancet 355:
1588–1596
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA,
Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J,
Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J,
Twelves C (2003) Oral capecitabine as an alternative to i.v. 5-
fluorouracil-based adjuvant therapy for colon cancer: safety results of
a randomized, phase III trial. Ann Oncol 14: 1735–1743
Smalley SR, Benedetti J, Williamson S, Robertson J, Fisher B, Martenson J,
Benson AB, Robert M, Cripps C, MacDonald J, for the SWOG (2003)
Intergroup 0144 – phase III trial of 5-FU based chemotherapy regimens
plus radiotherapy in postoperative adjuvant rectal cancer* Bolus 5FU vs
prolonged venous infusion before and after XRT+PVI vs bolus
5FU+leucovorin+levamisole before and after XRT+bolus 5FU+LV. Proc
Am Soc Clin Oncol 22: 251 (abstr 1006)
Taal BG, Van Tinteren H, Zoetmulder F, on behalf of the NACCP Group
(2001) Adjuvant 5FU plus levamisole in colonic or rectal cancer:
improved survival in stage II and III. Br J Cancer 85: 1437–1443
Tepper JE, O’Connell M, Niedzwiecki D, Hollis DR, Benson III AB,
Cummings B, Gunderson LL, MacDonald JS, Martenson JA, Mayer RJ
(2002) Adjuvant therapy in rectal cancer: analysis of stage, sex, and
local control – Final report of Intergroup 0114. J Clin Oncol 20:
1744–1750
Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J,
Cervantes A, Fagerberg J, Georgulias V, Husseini F, Jodrell D, Koralewski
P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso
R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J,
Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III
colon caner. New Engl J Med 352: 2696–2704
Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R,
Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Scholmerich J, Burger
HU, Verweij J (2000) Capecitabine, an oral fluoropyrimidine carbamate
with substantial activity in advanced colorectal cancer: results of a
randomized phase II study. J Clin Oncol 18: 1337–1345
Wolmark N, Rockette H, Fisher B, Wickeram DL, Redmond C, Fisher ER,
Jones J, Mamounas E, Ore L, Petrelli NJ, Spurr CL, Dimitrov NV,
Romond EH, Sutherland CM, Kardinal CG, De Fusco PA, Jochimsen P
(1993) The benefit of leucovorin-modulated fluorouracil as postoperative
Adjuvant chemotherapy in colorectal cancer
S De Placido et al
903
British Journal of Cancer (2005) 93(8), 896–904 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sadjuvant therapy for primary colon cancer: results from NSABP Protocol
C-03. J Clin Oncol 11: 1879–1887
Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickeram DL,
Bear HD, Aktins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999)
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin,
fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole
in patients with Dukes’ B and C carcinoma of the colon: results from
NSABP-C-04. J Clin Oncol 17: 3553–3559
Appendix
Complete list of all the investigators of the centres
referring to GOCSI-GruCOS cooperative groups
Oncologia Medica, Universita ` Federico II, Napoli (A Raffaele
Bianco, Sabino De Placido, Chiara Carlomagno, Rossella Lauria,
Alfredo Marinelli, Amalia Milano, Clorindo Pagliarulo, Stefano
Pepe, Giampaolo Tortora); Ospedale Mariano Santo, Cosenza
(Salvatore Palazzo, Virginia Liguori, Candida Mastroianni, Anto-
nio Rovito, Rosalbino Biamonte); Ospedale San Carlo, Potenza
(Luigi Manzione, Domenico Bilancia, Gerardo Rosati); Ospedale
Moscati, Avellino (Carlo Iannace, Francesco Caracciolo); Oncolo-
gia Medica, Benevento (Giovanni Pietro Ianniello, Vincenza
Tinessa, Angela Ruggiero, Luigi Leparulo, Ghassan Merkabaoui);
Oncologia Medica, Seconda Universita `, Napoli (Giuseppe Catala-
no, Fernando De Vita, Michele Orditura, Erika Martinelli, Floriana
Morgillo); Oncologia Medica, Universita ` de L’Aquila (Corrado
Ficorella, Paolo Marchetti); Oncologia Medica, Universita `, Sassari
(Antonio Farris, Giuseppina Sarobba, Gianni Sanna, M Grazia
Alicicco, Carlo Potzu); Ospedale SM Goretti, Latina (Modesto
D’Aprile, Giorgio Pistillucci, Franco Angelici, Venerina Sciacca);
Dipartimento di Oncologia Medica, Policlinico, Messina (Vincenzo
Adamo, Giuseppe Altavilla, Rosalba Rossello, Claudia Garipoli);
U.O. di Oncologia Medica, Universita ` Palermo (Nicola Gebbia,
Giuseppe Cicero, Fabio Fulfaro, M Rosaria Valerio); Cattedra di
Oncologia Medica, Universita ` Palermo (Sergio Palmeri, Carlo
Arcara, Giuseppe Badalamenti, Marina Vaglica); Oncologia Pre-
ventiva, Istituto Regina Elena, Roma (Silverio Tomao, Adriana
Romiti); Ospedale Santi Curro `, Catania (Roberto Bordonaro,
Giuseppe Failla); Oncologia Medica, Universita `, Cagliari
(Bruno Massidda, M Teresa Ionta); Oncologia Medica A, Istituto
Nazionale di Tumori, Napoli (Giuseppe Comella, Rossana
Casaretti); Ospedale Fatebenefratelli, Benevento (Tonino Pedicini,
Antonio Febbraro); Ospedale Civile Lamezia Terme (Ettore Greco);
Clinica Oncologica, Universita ` G D’Annunzio, Chieti (Stefano
Iacobelli, Luciana Irtelli, M Teresa Martino); Oncologia Medica A,
Istituto Regina Elena, Roma (Francesco Cognetti); Oncologia
Medica, II Facolta `, Universita ` La Sapienza, Roma (Salvatore
Lauro); Oncologia Medica B, Istituto Nazionale di Tumori, Napoli
(Giovanni Salvatore Bruni); Istituto Nazionale Tumori, Bari (Vito
Lorusso); Oncologia Medica, Universita `, Siena (Guido Francini);
Oncologia Medica, Universita `, Cagliari (Giovanni Mantovani);
Chirurgia Generale, Universita ` Federico II, Napoli (Giovanni
Persico, Andrea Renda, Luigi Bucci).
Complete list of all the investigators of the centres
referring to IRE cooperative group
Oncologia Medica B, Istituto Nazionale Tumori ‘Regina Elena’,
Roma (Massimo Lopez, Giancarlo Paoletti, Luigi Di Lauro,
Antonella Amodio, Paolo Foggi, Carolina Cauchi); Chirurgia
Addominale, Istituto Nazionale Tumori ‘Regina Elena’, Roma
(Eugenio Santoro, Maurizio Cosimelli, Fabio Carboni); Chirurgia
Generale, Istituto Nazionale Tumori ‘Regina Elena’, Roma
(Francesco Cavaliere, Pasquale Perri); U.O. Complessa Oncologia
‘B’, Universita ` La Sapienza, Roma (Enrico Cortesi, Giuliana
D’Auria, Adolfo De Pasquale Ceratti, Maria Laura Evangelista);
Chirurgia Generale, Ospedale ‘Dono Svizzero’, Formia (Giuseppe
Cardi, Alessandro Sparagna); Oncologia, Ospedale Belcolle,
Viterbo (Massimo Gemini, Domenico Padalino, Carlo Signorelli,
Elisabetta Capomolla); Chirurgia Generale, Ospedale Nuovo
Regina Margherita, Roma (Francesco Paolo Pantano, Carlo Tirelli);
Chirurgia Generale ‘Flajani’, Azienda Ospedaliera S Camillo-
Forlanini, Roma (Roberto Tersigni); Chirurgia Generale, Ospedale
Civile C Bernardini, Palestrina (Salvatore Naclerio); Chirurgia
Vascolare, Azienda Ospedaliera Universitaria Pisana (Savino
Gerardo Sardella); Oncologia Medica e Sperimentale, Istituto
Oncologico di Bari (Giuseppe Colucci).
Adjuvant chemotherapy in colorectal cancer
S De Placido et al
904
British Journal of Cancer (2005) 93(8), 896–904 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s